Mostrar el registro sencillo del ítem

dc.contributor.authorCernuda-Morollón E.
dc.contributor.authorRamón C.
dc.contributor.authorMartínez-Camblor P.
dc.contributor.authorSerrano-Pertierra E.
dc.contributor.authorLarrosa D.
dc.contributor.authorPascual J.
dc.date.accessioned2020-09-02T22:14:47Z
dc.date.available2020-09-02T22:14:47Z
dc.date.issued2015
dc.identifier10.1097/j.pain.0000000000000119
dc.identifier.citation156, 5, 820-824
dc.identifier.issn03043959
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3988
dc.descriptionOnabotulinumtoxinA (onabotA) has shown efficacy in chronic migraine (CM). Its mechanism of action, however, remains obscure. We have analysed whether treatment with onabotA is able to induce changes in interictal plasma calcitonin gene-related peptide (CGRP) concentrations, which have been shown to be increased in patients with CM. Calcitonin gene-related peptide levels were determined in samples obtained from the right antecubital vein using ELISA, outside a migraine attack and having taken no symptomatic medication in the previous 24 hours, in 83 patients with CM (average age 44 years; 94% females) before and 1 month after treatment with 155 to 195 U of onabotA. CGRP levels after onabotA treatment (median, 51.89 pg/mL; range, 199.4-10.2) were significantly lower as compared with CGRP levels obtained before onabotA treatment (median, 74.09 pg/mL; range, 241.0-11.4; P 0.001). Pretreatment CGRP levels in responders (76.85 pg/mL) were significantly higher than those seen in nonresponders (50.45 pg/mL; P 0.001). One month after treatment, the CGRP levels did not change in nonresponders (51.89 pg/mL; P not significant), but significantly decreased in responders (52.48 pg/mL; P 0.003). A number of demographic factors, clinical features, and comorbidities were not different in responders as compared with those of nonresponders. These results confirm that interictal CGRP levels can be of help in predicting the response to onabotA and suggest that the mechanism of action of onabotA in CM is the reversal of sensitization as a result of the inhibition of CGRP release. © 2015 International Association for the Study of Pain.
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.subjectCGRP
dc.subjectChronic migraine
dc.subjectMigraine
dc.subjectOnabotulinumtoxinA
dc.subjectbotulinum toxin A
dc.subjectcalcitonin gene related peptide
dc.subjectinterictal calcitonin gene related peptide
dc.subjectunclassified drug
dc.subjectacetylcholine release inhibitor
dc.subjectbiological marker
dc.subjectbotulinum toxin A
dc.subjectcalcitonin gene related peptide
dc.subjectadult
dc.subjectage
dc.subjectaged
dc.subjectArticle
dc.subjectcalcitonin blood level
dc.subjectclinical feature
dc.subjectcomparative study
dc.subjectdemography
dc.subjectdisease duration
dc.subjectdrug efficacy
dc.subjectdrug mechanism
dc.subjectdrug sensitization
dc.subjectenzyme inhibition
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectpriority journal
dc.subjectprotein determination
dc.subjecttransformed migraine
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectblood
dc.subjectchronic disease
dc.subjectmiddle aged
dc.subjectMigraine Disorders
dc.subjectpredictive value
dc.subjecttime
dc.subjectAcetylcholine Release Inhibitors
dc.subjectAdult
dc.subjectBiomarkers
dc.subjectBotulinum Toxins, Type A
dc.subjectCalcitonin Gene-Related Peptide
dc.subjectChronic Disease
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMigraine Disorders
dc.subjectPredictive Value of Tests
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.titleOnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
dc.typeArticle


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem